Gilder Gagnon Howe & Co’s Voyager Therapeutics VYGR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-94,551	Closed	-$1.08M	–	311
2023 Q2	$1.08M	Sell	94,551 -2,226	-2%	-$23K	0.01%	227
2023 Q1	$746K	Buy	96,777 +27,463	+40%	+$218K	0.01%	210
2022 Q4	$423K	Sell	69,314 -5,293	-7%	-$30.1K	0.01%	219
2022 Q3	$442K	Buy	74,607 +17,394	+30%	+$111K	0.01%	223
2022 Q2	$338K	Buy	+57,213	New	+$387K	0.01%	234
2018 Q1	–	Sell	-877	Closed	-$15K	–	306
2017 Q4	$15K	Sell	877 -1,340	-60%	-$23K	﹤0.01%	294
2017 Q3	$46K	Buy	+2,217	New	+$25K	﹤0.01%	274

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gilder Gagnon Howe & Co's VYGR Position: Q3 2023 in Review

Gilder Gagnon Howe & Co sold out of Voyager Therapeutics (VYGR) in Q3 2023, closing a stake of 94,551 shares — an estimated $1.08M sold.

Gilder Gagnon Howe & Co first reported a position in VYGR in Q3 2017 and held it in 7 quarters. The position peaked at $1.08M in Q2 2023. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2023.

Gilder Gagnon Howe & Co reported no remaining Voyager Therapeutics position as of Q3 2023 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 94,551 Voyager Therapeutics shares in Q3 2023, an estimated $1.08M.
Gilder Gagnon Howe & Co first reported a position in Voyager Therapeutics in Q3 2017 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Voyager Therapeutics position peaked at $1.08M in Q2 2023.
110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2023, filed 14 Nov 2023.